Leisman, Daniel E.
Handisides, Damian R.
Busse, Laurence W.
Chappell, Mark C.
Chawla, Lakhmir S.
Filbin, Michael R.
Goldberg, Marcia B.
Ham, Kealy R.
Khanna, Ashish K.
Ostermann, Marlies
McCurdy, Michael T.
Adams, Christopher D.
Hodges, Tony N.
Bellomo, Rinaldo
,
Article History
Received: 17 February 2024
Accepted: 12 April 2024
First Online: 18 April 2024
Declarations
:
: The trial was conducted in accordance with Good Clinical Practice guidelines, applicable local regulations, and Declaration of Helsinki principles. The respective independent institutional review boards reviewed the protocol, informed-consent form, and all other documents before study initiation.
: DEL, LWB, MCC, MRF, MBG, KRH, AKK, MO, MTC, and RB declare no competing interests. DRH, CDA, and TNH are employees of Innoviva Specialty Therapeutics, of which La Jolla Pharmaceutical Company (LJPC) is a subsidiary. LSC declares that he was formerly an employee of LJPC.